Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

被引:84
作者
Adi, Handoko [1 ]
Young, Paul M. [1 ]
Chan, Hak-Kim [1 ]
Agus, Helen [2 ]
Traini, Daniela [1 ]
机构
[1] Univ Sydney, Adv Drug Delivery Grp, Fac Pharm A15, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Sci G08, Sydney, NSW 2006, Australia
关键词
Mannitol; Ciprofloxacin; Dry powder inhaler (DPI); Cystic fibrosis; Antibiotics; Mucolytics; RECOMBINANT HUMAN DNASE; HIGH-DOSE IBUPROFEN; PSEUDOMONAS-AERUGINOSA; N-ACETYLCYSTEINE; LUNG-FUNCTION; MUCUS CLEARANCE; INHALATION; ANTIBIOTICS; SAFETY; INFECTION;
D O I
10.1016/j.ejps.2010.03.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to assess the potential of delivering a combination therapy, containing mannitol (a sugar alcohol with osmotic characteristics), and ciprofloxacin hydrochloride (an antibacterial fluoroquinolone), as a dry powder inhaler (DPI) formulation for inhalation. Single and combination powders were produced by spray drying ciprofloxacin and mannitol, from aqueous solution, at different ratios and under controlled conditions, as to obtain similar particle size distributions. Each formulation was characterised using laser diffraction, scanning electron microscopy, differential scanning calorimetry, dynamic vapour sorption, X-ray powder diffraction, and colloidal force microscopy. The in vitro aerosol performance of each formulation was studied using an Aerolizer (R) DPI device and a multi-stage liquid impinger (analysed using high performance liquid chromatography). In addition, a disk diffusion test was performed to assess the in vitro antimicrobial activity of each formulation and starting materials. All formulations had similar particle size distributions, however, the morphology, thermal properties and moisture sorption was dependent on the relative percentages of each component. In general, the combination formulation containing 50% (w/w) mannitol appeared to have the best aerosol performance, good stability and lowest particle cohesion (as measured by colloid probe microscopy). Furthermore, of the formulations tested, mannitol did not appear to alter the effectiveness of the ciprofloxacin antimicrobial activity to Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes. The combination of co-spray-dried mannitol and ciprofloxacin from a DPI is an attractive approach to promote mucous clearance in the respiratory tract while simultaneously treating local chronic infection, such as chronic obstructive pulmonary disease and cystic fibrosis. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 66 条
[1]   Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: A critical review [J].
Abbott J. ;
Hart A. .
Health and Quality of Life Outcomes, 3 (1)
[2]  
ADI H, 2009, DRUG DEV IND PHARM
[3]   Cospray dried antibiotics for dry powder lung delivery [J].
Adi, Handoko ;
Young, Paul M. ;
Chan, Hak-Kim ;
Stewart, Peter ;
Agus, Helen ;
Traini, Daniela .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (08) :3356-3366
[4]  
Anderson G, 1966, Br J Dis Chest, V60, P101, DOI 10.1016/S0007-0971(66)80006-2
[5]   A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol [J].
Anderson, SD ;
Brannan, J ;
Spring, J ;
Spalding, N ;
Rodwell, LT ;
Chan, K ;
Gonda, I ;
Walsh, A ;
Clark, AR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (03) :758-765
[6]   Lower airway inflammation in infants and young children with cystic fibrosis [J].
Armstrong, DS ;
Grimwood, K ;
Carlin, JB ;
Carzino, R ;
Gutierrez, JP ;
Hull, J ;
Olinsky, A ;
Phelan, EM ;
Robertson, CF ;
Phelan, PD .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (04) :1197-1204
[7]   Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance [J].
Bosquillon, C ;
Lombry, C ;
Préat, V ;
Vanbever, R .
JOURNAL OF CONTROLLED RELEASE, 2001, 70 (03) :329-339
[8]   Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: An overview of five Cochrane systematic reviews [J].
Bradley, JM ;
Moran, FM ;
Elborn, JS .
RESPIRATORY MEDICINE, 2006, 100 (02) :191-201
[9]  
Budavári Z, 1999, PHARMAZIE, V54, P861
[10]  
Burger A, 2000, J PHARM SCI-US, V89, P457, DOI 10.1002/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO